Keywords
How to Cite
Abstract
In this literature review we analyze the effectiveness of radiotherapy (as an independent method and in combination with surgery and chemotherapy) in the treatment of locally advanced non-small cell lung cancer. The postoperative adjuvant radiotherapy can increase overall survival and reduce the frequency of local recurrences in IIIA / N2 stage of NSCLC, however, its positive effect can be offset by the damage to surrounding structures. Modern high-tech equipment, improved planning systems, methods radiation doses delivery, and the fractionation regimen can improve the outcomes of radiation therapy. No bimodal treatment has shown advantages over other combinations. Some improvement in survival was noted in a number of studies using three-modal treatment, but it was also associated with an increase in the proportion of postoperative complications, especially after pneumonectomies. The heterogeneity of the IIIA / N2 NSCLC group and criteria for their operability present certain difficulties for a correct comparison of the treatment results, which requires further discussion. In most studies, insufficient attention has been paid to the influence of multimodal treatment on the quality of life of patients, which, taking into account comparable results of treatment, can be crucial in determining indications and contraindications.References
Арсеньев А.И., Аристидов Н.Ю., Барчук А.С., Канаев С.В. и соавт. Сравнительная оценка эффективности лечения больных раком лёгкого // Вопросы онкологии. - 2012. - Т. 58. - № 3. - С. 398-402.
Аскеров Н.М., Зейналов Р.С., Мусаев И.Н., Кязимов К.И. Эффективность химиолучевой терапии у больных немелкоклеточным раком лёгкого III стадии // Сибирский онкологический журнал. - 2010. - Т 1(37). - С. 61-63.
Деньгина Н.В. Оптимальные схемы химиолучевого лечения немелкоклеточного рака лёгкого III стадии (обзор литературы) // Поволжский онкол. вестник. -2015. - № 2. - С. 74-79.
Рагулин Ю.А. Современное состояние проблемы послеоперационной лучевой терапии рака лёгкого // Сибирский онкологический журнал. - 2015. - № 4. - С. 68-72.
Albain K.S., Swann R.S., Rusch V.W. et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial // Lancet. - 2009. - Vol. 374(9687). - Р. 379-386.
Auperin A., Le Pechoux С., Rolland E. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer // J. Clin. Oncol. - 2010. - Vol.13 (28). - P 2181-2190.
Belani C.P Choy H., Bonomi P et al. Combined chemo-radiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol // J. Clin. Oncol. - 2005. - Vol. 23. - P 5883-5891.
Billiet C., Dealuwe H., Peeters S. et al. Corrigendum to "Modern postoperative radiotherapy for stage III nonsmall cell lung cancer may improve local control and survival: A metaanalysis" // Radiotherapy and Oncology. - 2014. - Vol. 113(2). - P 300-301.
Bradley J.D., Paulus R., Komaki R. Standard-dose versus high-dose conformal radio-therapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-smallcell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study // Lancet Oncol. - 2015. - Vol. 16(2). - Р 187-199.
Burdett S., Rydzewska L., Tierney J. et al. on behalf of the PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer (Review) // Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD002142. CD002142.pub4. DOI: 10.1002/14651858
Corso C.D., Rutter C.E., Wilson L.D. et al. Reevaluation of the role of post-operative radiotherapy and the impact of radiation dose for non-small cell lung cancer using the National Cancer Database // J. Thorac. Oncol. - 2015. -Vol. 10 (1). - P 148-155.
Curran W.J., Paulus R., Langer C.J. et al. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410 // J. Natl. Cancer Inst. - 2011. - Vol. 103. - P 1452-1460.
Douillard J., Rosell R., De Lena M. et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial // Int. J. Radiat. Oncol. Biol. Phys. -2008. - Vol. 72. - P 695-701.
Eberhardt W.E.E., Pottgen C., Gauler T.C. et al. Phase III Study of Surgery Versus Definitive Concurrent Chemo-radiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemora-diotherapy (ESPATUE) // J. Clin. Jncol. - 2015. - Vol. 33(35). - P. 4194-4201.
Evison M., Clive A., Castle L. et al. Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group // J. Thorac. Oncol. -2017. - Vol. 12(9). - P 1434-1441.
Ezer N., Smith C.B., Galsky M.D. et al. Cisplatin vs. car-boplatin-based chemoradiotherapy in patients 65 years of age with stage III non-small cell lung cancer // Radiother. oncol. - 2014. - Vol. 2 (112). - P 272-278.
Lally B., Zelterman D., Colasanto J. et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database // J. Clin. Oncol. - 2006. - Vol. 24. - P 2998-3006.
Machtay M. Postoperative radiotherapy in non-small-cell lung cancer // The Lancet. - 1998. - Vol. 352 (9137). - P 1384-1385.
Mauguen A., Pignon J.P, Burdett S. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A reanalysis of meta-analyses of individual patients' data // Lancet Oncol. - 2013. - Vol. 14. - P 619- 626.
McElnay P.J., Choong A., Jordan E., et al. Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and metaanalysis of randomised trials // Thorax. - 2015. - Vol. 70(8). - P 764-768.
McWilliam A., Kennedy J., Hodgson C. et al. Radiation dose to heart base linked with poorer survival in lung cancer patients // Eur. J. Cancer. - 2017. - Vol. 9(85). - P 106-113.
Mikell J.L., Gillespie T.W., Hall W.A. et al. Post-Operative Radiotherapy (PORT) is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base // J. Thorac. Oncol. - 2015. - Vol. 10 (3). - P 462-471.
O'Rourke N. Concurrent chemoradiotherapy in non-small cell lung cancer / N. O'Rourke, M. Roque i Figuls, N. Farre Bernado, F. Macbeth // Cochrane Database Syst. Rev. - 2010. - Vol. 6. - CD002140.
Patel S.H., Ma Y, Wernicke A.G., Nori D et al. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer // Lung Cancer. - 2014. - Vol. 84. - P 156-160.
Pless M., Stupp R., Ris H.B. et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial // Lancet. - 2015. - Vol. 386(9998). - P 1049-1056.
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group // Lancet. - 1998. - Vol. 352 (9124). - P 257-263.
Ren Z., Zhou S., Liu Z., Xu S. Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis // J. Thorac. Dis. - 2015. - Vol. 7(8). - P 1414-1422.
Santana-Davila R., Devisetty K., Szabo A. et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: An analysis of Veterans Health Administration data // J. Clin. Oncol. - 2015. - Vol. 33(6). - P 567-574.
Shah A.A., Berry M.F., Tzao C. et al. Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer // The Ann. Thorac. Surg. -2012. - Vol. 93 (6). - P 1807-1812.
Thomas M., Rube C., Hoffknecht P Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer // Lancet Oncol. - 2008. - 9. - P. 636-648.
Van Meerbeeck J.P, Kramer G.W., Van Schil P.E. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-smallcell lung cancer // J. Natl. Cancer. Inst. - 2007. - Vol. 99. - P 442- 450.
Van Meerbeeck J.P The controversial role of surgery in stage III NSCLC // Lancet Oncol. - 2008. - Vol. 9(7). -P. 607-608.
Vokes E.E., Herndon J.E., Kelley M.J. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B // J. Clin. Oncol. - 2007. - Vol. 25. - P 1698-1704.
Xu Y.P., Xu X.L., Mao W.M. Is there a survival benefit in patients with stage IIIA (N2) non-small cell lung cancer receiving neoadjuvant chemotherapy and/or radiotherapy prior to surgical resection: a systematic review and metaanalysis // Medicine. - 2015. - Vol. 94(23). - е879.
Xu X.L., Chen W., Zhu S.M., Mao W.M. Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage 111A (N2) nonsmall-cell lung cancer: a meta-analysis and system review // Onco Targets Ther. - 2016. - Vol. 9. - P. 845-853.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019